Alkermes plc
ALKS
Jodie situation report
Alkermes plc's current read is isolated; its market group is not confirming.
The latest filing evidence is available. 0 of 1 group members are active now; 0 filing-linked outsiders are moving with the group, and 0 of 17 directly disclosed connections are confirming.
- Revenue increased 28.2% versus the comparable filing period.
- Operating income moved from a profit to a loss in the comparable period.
- Interest expense increased due to financing costs related to the Bridge Credit Agreement through the Avadel closing and interest on the Facilities.
- Initiation of Phase 3 Brilliance Studies in narcolepsy increased alixorexton development spend and related study costs.
Invalidation: The isolated read changes if ALKS's group or a disclosed connection begins moving with it.
Who this business touches
The relationships behind ALKS
Customers, suppliers, partners and competitors named in company filings—not inferred from headlines.
Depends on
BIIBBiogen Inc.partnerMay 5, 2026 ▾
“Under our license and collaboration agreement with Biogen, Biogen holds the exclusive, worldwide license to develop and commercialize VUMERITY.”
JAZZJazz Pharmaceuticals plcpartnerMay 5, 2026 ▾
“Pursuant to the settlement and license agreement entered into between Jazz Pharmaceuticals entities and Avadel entities in October 2025 (the “Avadel Settlement Agreement”), from October 1, 2025, Jazz receives a royalty of 3.85% (subject to certain adjustments…”
Depended on by
HRMYHarmony Biosciences Holdings, IsupplierFeb 24, 2026 ▾
“Additionally, Avadel Pharmaceuticals (acquired by Alkermes Plc in February 2026) launched a once nightly formulation version of sodium oxybate in June 2023.”
Filing peers
Companies whose filings use similar operating language.
Open the three relationships above to see Jodie’s filing proof. Pro unlocks 15 more links, every receipt, and alerts when connected names begin moving. Unlock the full network →
What is moving around it
Live connections
ALKS is currently a Leader in the organic co-movement group Specialty Pharmaceuticals. This group is discovered from market behaviour rather than assigned from an industry taxonomy. 3 filing-linked names are in the relationship map; none is currently confirmed as moving with the group.
This group is retained as the last observed read for ALKS; it is not active in the latest market snapshot.